A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

<p>Abstract</p> <p>Background</p> <p>Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the...

Full description

Bibliographic Details
Main Authors: Hamid Omid, Schmidt Henrik, Nissan Aviram, Ridolfi Laura, Aamdal Steinar, Hansson Johan, Guida Michele, Hyams David M, Gómez Henry, Bastholt Lars, Chasalow Scott D, Berman David
Format: Article
Language:English
Published: BMC 2011-11-01
Series:Journal of Translational Medicine
Subjects:
Cytotoxic T-lymphocyte antigen-4
FoxP3
indoleamine 2,3-dioxygenase
ipilimumab
melanoma
tumor biomarker
tumor-infiltrating lymphocytes
Online Access:http://www.translational-medicine.com/content/9/1/204

Internet

http://www.translational-medicine.com/content/9/1/204

Similar Items